Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | USP2 | O75604 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291505 | 0.86 | KDM4E (0.68) | KDM4EHSD17B10USP2TSHRMEN1 | |
| SCHEMBL292369 | 0.83 | CSNK2A1 (0.68) | KDM4EHSD17B10USP2TSHRMEN1 | |
| SCHEMBL298156 | 0.80 | CSNK2A1 (0.85) | KDM4EHSD17B10USP2TSHRMEN1 | |
| SCHEMBL27775753 | 0.79 | CSNK2A1 (0.65) | KDM4EHSD17B10USP2TSHRMEN1 | |
| SCHEMBL297749 | 0.79 | CSNK2A1 (0.87) | KDM4EHSD17B10USP2TSHRMEN1 | |
| SCHEMBL3329830 | 0.79 | KDM4E (0.64) | KDM4EHSD17B10USP2TSHRMEN1 | |
| SCHEMBL11939089 | 0.77 | CSNK2A1 (0.67) | KDM4EHSD17B10USP2TSHRMEN1 | |
| SCHEMBL290812 | 0.77 | CSNK2A1 (0.72) | KDM4EHSD17B10USP2TSHRMEN1 | |
| SCHEMBL19207419 | 0.76 | CSNK2A1 (0.64) | KDM4EHSD17B10USP2TSHRMEN1 | |
| SCHEMBL300826 | 0.76 | KDM4E (0.66) | KDM4EHSD17B10USP2TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | SIGNAL PHARM LLC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3659599-B1 | 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-B]PYRAZIN-2(1H)-ONE FOR USE IN THE TREATMENT OF GLIOBLASTOMA MULTIFORME | SIGNAL PHARM LLC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-11-09 | — | — | US | disclosed |
| EP-3466423-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-107976546-B | Inhibition of phosphorylation of TOR kinase inhibitory Activity markers PRAS40, GSK 3-beta, or P70S6K1 | 西格诺药品有限公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3659599-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| CN-110721186-A | Treatment of prostate cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-107157990-B | Treatment of cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-2531194-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-20 | — | — | US | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| WO-2011097333-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| CN-101679432-A | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2010-03-24 | — | — | CN | disclosed |
| EP-2078018-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | STK11, STK16, STK10 | KDM4E 3306/4885HSD17B10 2006/4885USP2 1337/4885 |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | MTOR, TTK, BRCA1 | KDM4E 1384/4885HSD17B10 1435/4885USP2 1392/4885 |
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | KDM4E 877/4885HSD17B10 2971/4885USP2 1347/4885 |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | KDM4E 1690/4885HSD17B10 1113/4885USP2 2215/4885 |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | MTOR, TTK, RICTOR | KDM4E 877/4885HSD17B10 2971/4885USP2 1347/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | KDM4E 2069/4885HSD17B10 1007/4885USP2 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.